Biofrontera FY26 Q1 pretax profit more than doubles to EUR 2.2 million

• Biofrontera swung to pretax profit of EUR 2.2 million as revenue fell 29.76% to EUR 4.05 million.
• EBITDA climbed 14.6% to EUR 1.16 million, while revenue from continuing operations rose 13.4% to EUR 3.71 million.
• Continuing-operations EBITDA turned positive at EUR 143,000, while discontinued-operations pretax profit more than doubled to EUR 2.16 million.
• Other income included a EUR 1.01 million earn-out tied to the Biofrontera Inc. asset sale, with FDA transfer approval expected by end-June 2026.
• Launched Ovixan in the UK; reaffirmed 2026 guidance for EUR 14 million–EUR 16 million revenue, adjusted EBITDA of EUR 3.5 million–EUR 5.1 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera AG published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.